Journal profile · Oncology
Clinical Breast Cancer
ISSN 1526-8209 · eISSN 1938-0666 · Elsevier · UNITED STATES · Bimonthly · Founded 2000
Clinical Breast Cancer: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.6; hybrid open access; APC about USD 3,470; median 90 days to acceptance (102 articles, last 24 months); community-reported acceptance: fairly easy; 245 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical Breast Cancer is published by Elsevier and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Breast Lesions and Carcinomas and HER2/EGFR in Cancer Research, together about 44.1% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Clinical Breast Cancer is a peer-reviewed journal dedicated to publishing original articles on all aspects of clinical and translational research related to breast cancer. The journal focuses on the latest scientific advancements in the detection, diagnosis, prevention, and treatment of breast cancer.Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.Manuscripts reporting non-clinical or translational studies must include functional experiments that directly support the study’s conclusions. Purely correlative studies without functional validation or mechanistic insights will not be considered. All research should demonstrate a clear and direct relevance to the clinical setting, highlighting potential implications for patient care or therapeutic development.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editorial board by country: 7 in mainland China (about 14%); most named United States 35, Mainland China 7, Brazil 4, United Kingdom 2, India 1 (51 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology24.5%
- Breast Lesions and CarcinomasMedicine10.5%
- HER2/EGFR in Cancer ResearchMedicine9.2%
- Cancer Treatment and PharmacologyMedicine8.4%
- Breast Implant and ReconstructionMedicine6.5%
- Advanced Breast Cancer TherapiesMedicine5.5%
- Estrogen and related hormone effectsBiochemistry, Genetics and Molecular Biology3.3%
- Global Cancer Incidence and ScreeningMedicine3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.6LetPub ·
- Impact factor (publisher)
- 2.7Publisher website ·
- CiteScore 2026-06
- 4.9LetPub ·
- CiteScore (publisher)
- 4.9Publisher website ·
- SJR 2026-06
- 0.93LetPub ·
- SNIP 2026-06
- 0.93LetPub ·
- h-index
- 64LetPub ·
- h-index
- 99OpenAlex ·
- i10-index
- 1,622OpenAlex ·
- 2-year mean citedness
- 2.37OpenAlex ·
- Self-citation rate
- 3.7%LetPub ·
- Share of gold OA articles
- 14.34%LetPub ·
Volume
- Articles per year
- 188LetPub ·
Articles by year OpenAlex count · 3,387 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 172 | 62 | 36 |
| 2025 | 245 | 66 | 441 |
| 2024 | 234 | 76 | 1,069 |
| 2023 | 171 | 64 | 1,300 |
| 2022 | 161 | 42 | 1,462 |
| 2021 | 187 | 61 | 2,850 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
90 daysMedian, submission to acceptance · P25–P75 54 days – 144 days
- Acceptance to online
- median 3 days (102 articles)
- Submission to online
- median 101 days
- Sample
- 102 articles with submission and acceptance dates (511 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 3 monthsLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 59 daysPublisher website ·
- Submission to acceptance
- 87 daysPublisher website ·
- Acceptance to publication
- 5 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,470 / EUR 3,250 / GBP 2,780 / JPY 430,380 | — | — | |
| Publisher website | USD 3,750 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 8,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
Article types accepted6
- commentaryCommentary: Commentary articles present original perspectives on novel or controversial clinical topics that warrant rapid dissemination.Length not stated
- original studyOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications.Length not stated
- perspectivePerspective: Perspective articles provide focused discussions of important clinical topics from a specific viewpoint or opinion.Length not stated
- reviewOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- review articleOriginal Study: Original Study articles present results of original clinical research and/or translational research with clear clinical implications. These arti…Length not stated
- systematic reviewSystematic Review: Systematic Review articles rigorously collect, evaluate, and synthesize data from multiple studies to provide evidence-based conclusions on c…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Ethics in publishing Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of one reviewer for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Rea…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2000
- ISSN
- 1526-8209
- Electronic ISSN
- 1938-0666
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Clinical Breast Cancer
What CAS zone is Clinical Breast Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical Breast Cancer is in Zone 3 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical Breast Cancer?
The latest impact factor listed by LetPub is 2.6; CiteScore 4.9, h-index 99.
How long does peer review take at Clinical Breast Cancer?
Based on the dates recorded on 102 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 90 days (interquartile range 54–144 days); authors report an average review time of about 3 months; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical Breast Cancer?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 8,000 words; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical Breast Cancer based?
Of the 51 board members whose country the journal's board page names, 7 (about 14%) are in mainland China; the countries named most often are United States (35), Mainland China (7) and Brazil (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical Breast Cancer?
According to LetPub and DOAJ records, Clinical Breast Cancer is indexed in SCIE and Scopus.
Is Clinical Breast Cancer open access, and what is the APC?
Clinical Breast Cancer is a hybrid journal. For open-access publication: APC about USD 3,470.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .